Cardio-oncology: a cardiologist's view on the problem of endovascular treatment of patients with coronary artery disease and severe aortic valve stenosis combined with cancer: a literature review

CARDIOVASCULAR THERAPY AND PREVENTION, Journal Year: 2024, Volume and Issue: 23(9), P. 4051 - 4051

Published: Oct. 24, 2024

Cardio-oncology is a new medical direction which responsible for the prevention of development, diagnosis and treatment cardiovascular disease (CVD) in patients with cancer. The prevalence cardiac pathology cancer turned out to be unexpectedly high, while only half two systems are referred cardiologist consultation receive optimal therapy. coincidence risk fa­ctors CVD suggests that these diseases have common underlying biological molecular mechanisms. Antitumor therapy radiation can also contribute onset progression CVD. Diagnosis coronary artery (CAD) difficult, since this group often lacks typical angina pain, most complaint dyspnea. Endovascular surgery CAD severe aortic valve stenosis an effective safe method treating concomitant However, given heterogeneity fact were not included randomized trials studying treatment, further research required area. Aim. To analyze literature on etiopathogenesis patients, as well clinical features potential innovative endovascular technologies. Conclusion. For management such comorbid participation multidisciplinary team personalized approach each patient necessary.

Language: Английский

---

Association between prostate cancer and myocardial infarction management and post-infarction outcomes: A Norwegian registry study

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 5, 2024

Abstract Background and aims Prostate cancer (PCa) is the most frequently diagnosed in men Norway as survival rates improve cardiovascular disease (CVD) has emerged a primary cause of morbidity mortality, including acute myocardial infarction (AMI). Cancer CVD share some important risk factors PCa treatment may increase CVD. The aim this study was to compare invasive management, in-hospital complications, major adverse events (MACE), re-infarction death, well prescription guideline recommended secondary pharmacological prevention after an AMI between patients general male population. Methods Data included nation-wide registry data identify all males 40-85 years who had their first during 2013-2019. We compared outcomes those with localized 2004-2019 population using logistic cause-specific Cox regression. Results 34,362 were included, whom 1405 (4.1%) PCa. No differences observed management or medical post-AMI non-cancer patients. While lower overall complications (OR 0.77; 0.64-0.92), they experienced increased serious bleeding 1.66; 1.08-2.44) no difference MACE events. better 1-year (HR 0.82; 0.69-0.98). Conclusions There evidence reduced quality care for Norway. These findings support usual patients, but attention risk. Key learning points What known Evidence from studies evaluating have found that are more likely receive poorer worse outcomes, one cancers men, improve, infarction. adds non-metastatic prostate when at higher following year. Overall, except bleeding, which likely. Non-metastatic should individualized consideration bleeding. Non-standard abbreviations acronyms ADT = androgen deprivation therapy; CCI Charlson comorbidity index; NorPD Norwegian Prescription Database; NORMI Myocardial Infarction Quality Registry

Language: Английский

---

Cancer Prevention and Early Detection in Patients With Cardiovascular Disease

JACC CardioOncology, Journal Year: 2024, Volume and Issue: 6(6), P. 962 - 964

Published: Dec. 1, 2024

Language: Английский

---